Tags

Type your tag names separated by a space and hit enter

Early investigational β3 adreno-receptor agonists for the management of the overactive bladder syndrome.
Expert Opin Investig Drugs. 2015; 24(10):1299-306.EO

Abstract

INTRODUCTION

Antimuscarinic drugs form the mainstay of medical treatment for Overactive bladder Syndrome (OAB). With a proven efficacy but poor tolerability, other treatment modalities have been sought. Recent concerns regarding cumulative anticholinergic load and risk of dementia have provided further impetus to find novel OAB treatments. β3-adrenoceptor (β3-AR) agonists improve OAB symptoms by relaxing bladder tissue. As such, the search is underway to develop β3-AR agonist drugs for the treatment of OAB.

AREAS COVERED

The authors discuss studies on the only approved β3-AR agonist, mirabegron, followed by reports on β3-AR agonists in development, namely ritobegron and solabegron. The authors also discuss the early investigations of novel and putative β3-AR agonist drugs which are being assessed for management of OAB, including aryloxypropanolamine, TRK-380, AJ-9677, BRL37344 and CL 316,243. These investigations have also highlighted alternative unexpected modes of β3-AR action.

EXPERT OPINION

There are a number of β3-ARs in the pipeline but it is uncertain which, if any, will come to market and aid in the management of OAB. A picture of a β3-AR dual action which was unknown previously is emerging. Overall, the authors believe that it is an exciting time for the pharmacological management of OAB with new drugs on the horizon which could potentially improve the patient's quality of life.

Authors+Show Affiliations

a King's College Hospital, Urogynaecology Department , London SE5 9RS, UK +44 20 3299 3568 ; Gans.t@nhs.net.a King's College Hospital, Urogynaecology Department , London SE5 9RS, UK +44 20 3299 3568 ; Gans.t@nhs.net.a King's College Hospital, Urogynaecology Department , London SE5 9RS, UK +44 20 3299 3568 ; Gans.t@nhs.net.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

26292923

Citation

Thiagamoorthy, Ganesh, et al. "Early Investigational Β3 Adreno-receptor Agonists for the Management of the Overactive Bladder Syndrome." Expert Opinion On Investigational Drugs, vol. 24, no. 10, 2015, pp. 1299-306.
Thiagamoorthy G, Giarenis I, Cardozo L. Early investigational β3 adreno-receptor agonists for the management of the overactive bladder syndrome. Expert Opin Investig Drugs. 2015;24(10):1299-306.
Thiagamoorthy, G., Giarenis, I., & Cardozo, L. (2015). Early investigational β3 adreno-receptor agonists for the management of the overactive bladder syndrome. Expert Opinion On Investigational Drugs, 24(10), 1299-306. https://doi.org/10.1517/13543784.2015.1076390
Thiagamoorthy G, Giarenis I, Cardozo L. Early Investigational Β3 Adreno-receptor Agonists for the Management of the Overactive Bladder Syndrome. Expert Opin Investig Drugs. 2015;24(10):1299-306. PubMed PMID: 26292923.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Early investigational β3 adreno-receptor agonists for the management of the overactive bladder syndrome. AU - Thiagamoorthy,Ganesh, AU - Giarenis,Ilias, AU - Cardozo,Linda, Y1 - 2015/08/14/ PY - 2015/8/22/entrez PY - 2015/8/22/pubmed PY - 2016/5/6/medline KW - early investigation KW - novel KW - overactive bladder syndrome KW - overactive bladder syndrome management KW - β3 adrenoceptor SP - 1299 EP - 306 JF - Expert opinion on investigational drugs JO - Expert Opin Investig Drugs VL - 24 IS - 10 N2 - INTRODUCTION: Antimuscarinic drugs form the mainstay of medical treatment for Overactive bladder Syndrome (OAB). With a proven efficacy but poor tolerability, other treatment modalities have been sought. Recent concerns regarding cumulative anticholinergic load and risk of dementia have provided further impetus to find novel OAB treatments. β3-adrenoceptor (β3-AR) agonists improve OAB symptoms by relaxing bladder tissue. As such, the search is underway to develop β3-AR agonist drugs for the treatment of OAB. AREAS COVERED: The authors discuss studies on the only approved β3-AR agonist, mirabegron, followed by reports on β3-AR agonists in development, namely ritobegron and solabegron. The authors also discuss the early investigations of novel and putative β3-AR agonist drugs which are being assessed for management of OAB, including aryloxypropanolamine, TRK-380, AJ-9677, BRL37344 and CL 316,243. These investigations have also highlighted alternative unexpected modes of β3-AR action. EXPERT OPINION: There are a number of β3-ARs in the pipeline but it is uncertain which, if any, will come to market and aid in the management of OAB. A picture of a β3-AR dual action which was unknown previously is emerging. Overall, the authors believe that it is an exciting time for the pharmacological management of OAB with new drugs on the horizon which could potentially improve the patient's quality of life. SN - 1744-7658 UR - https://www.unboundmedicine.com/medline/citation/26292923/Early_investigational_β3_adreno_receptor_agonists_for_the_management_of_the_overactive_bladder_syndrome_ L2 - https://www.tandfonline.com/doi/full/10.1517/13543784.2015.1076390 DB - PRIME DP - Unbound Medicine ER -